Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma
IntroductionSubcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed/refractory (R/R) SPTCL has been rarely discussed.MethodsThis study aims to compare the efficacy of conventional chemotherapy and...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1476875/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136387123806208 |
|---|---|
| author | Chao Chen Jingjing Yin Minghui Duan Wei Wang Danqing Zhao Chong Wei Congwei Jia Wei Zhang Daobin Zhou Yan Zhang |
| author_facet | Chao Chen Jingjing Yin Minghui Duan Wei Wang Danqing Zhao Chong Wei Congwei Jia Wei Zhang Daobin Zhou Yan Zhang |
| author_sort | Chao Chen |
| collection | DOAJ |
| description | IntroductionSubcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed/refractory (R/R) SPTCL has been rarely discussed.MethodsThis study aims to compare the efficacy of conventional chemotherapy and chemo-free immunomodulatory regimen for R/R SPTCL. We retrospectively reviewed the patients with first relapse or primary refractory SPTCL between September 1997 and October 2020.ResultsA total of 19 patients with R/R SPTCL with a median age of 34 were included. All patient received the first-line chemotherapy-based treatment with a median PFS of 1.8 months. In these patients, 16 received salvage second-line treatment with an ORR of 31.3% and a median TTNT of 3.0 months. 13 of these 16 patients received chemotherapy-based treatment, resulting in a median TTNT of 2.4 months. 2 of these 16 patients received allogeneic hematopoietic stem cell transplantation and achieved long term complete remission (CR). In third-line treatment, 7 patients received chemotherapy-based regimen and 6 received chemo-free regimen such as VRMP (bortezomib, lenadomide and methylprednisolone) regimen and CsA plus IFNα regimen. The median TTNT of chemotherapy and chemo-free group were 3.2 months and not reached, respectively.DiscussionChemo-free group had a better TTNT than chemotherapy group (p=0.007). The use of chemotherapy-free regimens for R/R SPTCL appears promising and warrants further validation. |
| format | Article |
| id | doaj-art-561e771b3ea8499c85da3d084db7ebe5 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-561e771b3ea8499c85da3d084db7ebe52024-12-09T06:28:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-12-011510.3389/fimmu.2024.14768751476875Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphomaChao Chen0Jingjing Yin1Minghui Duan2Wei Wang3Danqing Zhao4Chong Wei5Congwei Jia6Wei Zhang7Daobin Zhou8Yan Zhang9Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaIntroductionSubcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed/refractory (R/R) SPTCL has been rarely discussed.MethodsThis study aims to compare the efficacy of conventional chemotherapy and chemo-free immunomodulatory regimen for R/R SPTCL. We retrospectively reviewed the patients with first relapse or primary refractory SPTCL between September 1997 and October 2020.ResultsA total of 19 patients with R/R SPTCL with a median age of 34 were included. All patient received the first-line chemotherapy-based treatment with a median PFS of 1.8 months. In these patients, 16 received salvage second-line treatment with an ORR of 31.3% and a median TTNT of 3.0 months. 13 of these 16 patients received chemotherapy-based treatment, resulting in a median TTNT of 2.4 months. 2 of these 16 patients received allogeneic hematopoietic stem cell transplantation and achieved long term complete remission (CR). In third-line treatment, 7 patients received chemotherapy-based regimen and 6 received chemo-free regimen such as VRMP (bortezomib, lenadomide and methylprednisolone) regimen and CsA plus IFNα regimen. The median TTNT of chemotherapy and chemo-free group were 3.2 months and not reached, respectively.DiscussionChemo-free group had a better TTNT than chemotherapy group (p=0.007). The use of chemotherapy-free regimens for R/R SPTCL appears promising and warrants further validation.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1476875/fullsubcutaneous panniculitis-like T-cell lymphomachemo-free regimenchemotherapyimmunotherapyT-cell lymphoma |
| spellingShingle | Chao Chen Jingjing Yin Minghui Duan Wei Wang Danqing Zhao Chong Wei Congwei Jia Wei Zhang Daobin Zhou Yan Zhang Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma Frontiers in Immunology subcutaneous panniculitis-like T-cell lymphoma chemo-free regimen chemotherapy immunotherapy T-cell lymphoma |
| title | Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma |
| title_full | Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma |
| title_fullStr | Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma |
| title_full_unstemmed | Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma |
| title_short | Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma |
| title_sort | chemo free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed refractory subcutaneous panniculitis like t cell lymphoma |
| topic | subcutaneous panniculitis-like T-cell lymphoma chemo-free regimen chemotherapy immunotherapy T-cell lymphoma |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1476875/full |
| work_keys_str_mv | AT chaochen chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT jingjingyin chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT minghuiduan chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT weiwang chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT danqingzhao chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT chongwei chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT congweijia chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT weizhang chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT daobinzhou chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma AT yanzhang chemofreesalvagetreatmentoutperformstraditionalchemotherapyinadvancedlinesofrelapsedrefractorysubcutaneouspanniculitisliketcelllymphoma |